InVitro International (OTCQB: IVRO) reported first half fiscal year 2025 financial results, highlighting modest sales growth and ongoing efforts to advance non-animal testing technologies. The company recorded sales of $440,650, representing a 4.4% increase compared to the same period in the previous fiscal year.
Despite the sales increase, net income declined by 24.7% to $49,239, which the company attributes to inflationary pressures and increased OTCQB listing costs. CEO W. Richard Ulmer emphasized the potential for growth in non-animal test technologies, citing recent legislative developments supporting alternative testing methods.
Global regulatory trends are increasingly favoring non-animal testing, with Canada recently passing legislation following Europe's 2013 ban on cosmetics developed through animal testing. The United States appears poised to adopt similar regulations, potentially expanding restrictions to over-the-counter personal care products like shampoos and skin care items.
IVRO's testing technologies focus on producing corrosivity and ocular/dermal irritation data that correlate with animal and human test results. The company sees emerging opportunities as regulatory agencies become more receptive to scientifically validated alternative testing methods.
The financial report and strategic positioning suggest IVRO is strategically aligned with growing international momentum toward reducing animal testing in research and product development.
